Patenting in Climate Tech: Why Patent Counts Mislead, and What Actually Protects Capital

A pitch deck that leads with "200 granted patents" is telling you almost nothing about whether that IP will defend a margin, survive a challenge, or be worth anything in a downside. Three numbers from the last 18 months explain why, and they should change how you diligence climate-tech IP.

The Vanity-Count Trap, Now Quantified

The instinct to count patents is understandable and almost always wrong. The hard data: when a US patent is actually challenged at the Patent Trial and Appeal Board and reaches a final written decision, roughly 70% of the time every instituted claim is cancelled (FY2024; about 64% in the first half of FY2025). In March and April 2025, the board voided 72% and 85% of instituted claims respectively. The escape hatch barely functions: motions to amend claims are granted only about 24% of the time.

Read that as an investor, not a lawyer. A granted patent is a presumption, not a moat. The portfolio that matters is the slice that would survive a motivated adversary's validity attack, and raw count tells you nothing about how thick that slice is. The right question in diligence is not "how many?" but "how many would still stand after an IPR, and do those cover the part of the system that earns the margin?"

The Achilles Heel Almost No IC Memo Prices: Foreign Prior Art

Here is the shift that has quietly rewritten the risk equation. In 2025, Asia accounted for 56% of all international (PCT) patent filings, the first time the centre of gravity in global innovation formally crossed the Pacific. In green technology the gap is starker still: China published roughly 555,000 green patent applications between 2016 and 2023, against about 200,000 for Japan and 157,000 for the United States.

Why should a buy-side investor care about filing league tables? Because prior art is global, and it is increasingly written in Mandarin. A US-centric portfolio drafted with broad claims, without searching the exploding base of Chinese and other non-US filings, is carrying a latent defect. When a sophisticated counterparty wants to invalidate those claims, they will fund a search through the international nooks and crannies and surface prior art the USPTO never considered. The result, as IP counsel now warn, is the illusion of patent protection rather than the real thing, exposed at exactly the wrong moment: a licensing standoff, an infringement suit, or your own exit diligence.

This is not theoretical. 2025 saw Maxeon Solar litigating against Canadian Solar and REC over TOPCon cell technology, and Tigo Energy settle with SMA over solar rapid-shutdown patents. The lesson for an allocator is that IP exposure is a live, cash-flow-relevant risk, and a portfolio's geographic prior-art exposure belongs on the diligence checklist next to freedom to operate.

What Actually Carries Value

Claims scope and freedom to operate

Wide, field-agnostic claims look impressive and invalidate easily. Narrow claims drafted to the specific field of use are less glamorous and far more durable. Pair that with a documented freedom-to-operate position: a startup can hold a thick portfolio and still need a license from a third party to run its own process. Many climate funds wave FTO through. The ones that do not are the ones that avoid discovering, post-Series C, that royalty stacking has quietly eaten their IRR.

Process IP at the choke point

In climate tech it is rarely the end product that defines competitive position. It is the catalyst, the membrane, the separation step, the integration know-how that sets OPEX. Entire markets in biofuels and renewables were shaped not by who invented a molecule but by who controlled the process to make it economically. Owning the "how" at the cost-curve choke point is more defensible than owning the "what."

Patents as Capital, Not Legal Cost

The defensive lens is only half the story. Well-structured IP is increasingly a financing instrument. IP-backed lending lets companies borrow against patents as collateral, and IP-insured debt structures can price below conventional venture debt for mature-stage companies, because an insurance backstop de-risks the valuation. For a capital-intensive climate business, that is the difference between dilutive equity and cheaper non-dilutive debt. Strong IP also raises M&A multiples (acquirers pay for freedom from litigation) and is among the few assets with residual value in a liquidation. Patents are not a sunk legal line item; they are a capital-structure variable.

The IP Bankability Scorecard

To make this operational, we score climate-tech portfolios on seven weighted factors rather than counting filings. Each is rated 1 to 5; the weighted total maps to a 0 to 100 bankability score and a tier.

Factor	Weight	What it tests
Freedom to Operate	20%	Clean FTO map vs blocking IP / royalty stacking
Claim scope precision	15%	Field-of-use claims vs broad-and-vulnerable
Foreign prior-art exposure	15%	Resilience to non-US (esp. Chinese) prior art
Process / choke-point coverage	15%	Owns the step that sets the cost curve
Enforceability / IPR resilience	15%	Would claims survive the ~70% kill rate?
Jurisdictional coverage	10%	US + EU + CN and key manufacturing markets
Residual / collateral value	10%	Licensable, financeable, survives distress

Tiers: 80 to 100 bankable moat (underwrite with confidence); 60 to 79 enabling; 40 to 59 defensive (do not pay for it in the multiple); below 40 decorative, treat IP value as roughly zero.

What Investors Rarely Ask, But Should

Most IP diligence stops at "portfolio reviewed by counsel." The sharper questions: How enforceable is this IP in the jurisdictions that matter, and has anyone searched the foreign prior-art base that could sink it? What share of the value chain does it actually choke? How fast could a competitor design around it, in 18 months or five years? Could it be licensed or sold to recover value if the company fails? These are investment questions tied directly to IRR and DPI, not legal housekeeping.

The Bottom Line

In climate tech, the value of patents is not in the filing cabinet. It is in how few claims would survive a challenge, whether those claims sit at the choke point, how exposed they are to a global prior-art base that now skews to Asia, and whether the portfolio can be financed rather than just defended. Score that, and you will price IP closer to what it is actually worth, which is usually a long way from the number on the pitch deck.

Climate-Tech IP: Investor FAQ

How should investors value patents in a climate-tech company?

Not by count. Weight enforceability (would claims survive an IPR, where ~70% of challenged patents lose all claims), freedom to operate, coverage of the cost-curve choke point, exposure to foreign prior art, and whether the IP is financeable as collateral. A small, well-scoped portfolio can be worth far more than hundreds of broad filings.

What is the patent invalidation rate at the PTAB?

The Patent Trial and Appeal Board cancelled all instituted claims in roughly 70% of final written decisions in FY2024 (about 64% in the first half of FY2025), and motions to amend are granted only ~24% of the time. A granted patent is a presumption, not a guarantee.

Why is foreign prior art a risk for US patents?

Asia now files most of the world's patents (56% of PCT applications in 2025) and dominates green-tech filings. Broad US claims drafted without searching that base can be invalidated when an adversary surfaces non-US prior art, turning apparent protection into none.

What is freedom to operate (FTO) and why does it matter?

FTO is the ability to commercialise without infringing someone else's IP. A company can own many patents and still need a third-party license to run its own process; unresolved FTO creates royalty-stacking and litigation risk that erodes returns.

Can patents be used as collateral or financing?

Yes. IP-backed lending uses patents as collateral, and IP-insured debt can price below conventional venture debt for mature-stage companies, offering non-dilutive capital. Strong IP also lifts M&A multiples and retains residual value in distress.

Sources: USPTO PTAB FY2025 statistics; IPWatchdog; Finnegan; WIPO World IP Report 2026; Foley & Lardner (Energy Current); IAM Media. Scoring weights are Trident's framework, not a standard. This is analysis, not legal or investment advice.